Aseptuva raises $2.4M Seed (Switzerland, Sep 2026)
Reach the investors backing rounds like this
Backed by Simon Michel, Roger Nitsch +5 more · verified emails and LinkedIn on Datapile
Following a CHF 2.4 million seed round, Aseptuva progressed to preclinical validation - Startupticker.ch
Aseptuva is a Swiss-UK Medtech startup developing a targeted Far-UVC disinfection technology to prevent hospital-acquired infections, particularly bloodstream infections associated with intravenous catheters. Their technology aims to reduce infection risk and antibiotic reliance by disinfecting at the catheter-entry site. The company is focused on preventing deaths, shortening hospital stays, and reducing healthcare costs.
Following a CHF 2.4 million seed round, Aseptuva progressed to preclinical validation Startupticker.ch
| Oct 03, 2026 | Africa Finance Corporation | $431.0M | Debt | Switzerland |
| Oct 01, 2026 | FOOD FOUNDERS Studio | $4.0M | — | Switzerland |
| Sep 23, 2026 | Relai | $2.5M | — | Switzerland |
| Sep 18, 2026 | Piomic | $25.0M | Growth | Switzerland |
11,982 investors back startups in Switzerland
You just read who funded Aseptuva. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.